A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone

Clinical Nephrology

Volumn 46, Issue 4, 1996, Pages 219-224

  Rayner, B L ^a   Byrne, M J ^a   Van Zyl Smit, R ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Diet; Hyperlipidemia; Idiopathic membranous nephropathy; Nephrotic syndrome; Simvastatin

Indexed keywords

CHOLESTEROL; CREATININE; EDETATE CHROMIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN; SERUM ALBUMIN; SIMVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET THERAPY; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, DIETARY; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; NEPHROTIC SYNDROME; PROSPECTIVE STUDIES; SERUM ALBUMIN; SIMVASTATIN; TIME FACTORS;

EID: 0029811045     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Baxter JH 1962 Hyperlipoproteinaemia in nephrosis. Arch Int Med 109: 742-757
2. Bridgman JF, Rosen SM, Thorp JM 1972 Complications during clofibrate therapy of neophrotic syndrome hyperlipoproteinaemia. Lancet 2: 506-509.34
3. Calandra S, Gherardi E, Fainaru M, Guaitani A, Bartosek I. Secretion of lipoproteins, apolipoprotein A-1 and apolipoprotein E by isolated and perfursed liver of rat with experimental nephrotic syndrome. Biochim Biophys Acta 605: 331-338
4. Cattran DC, Delmore T, Roscoe J et al. 1989 A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 320: 210-215
5. Chan MK, Persaud JW, Ramdial L, Varghese Z, Sweny P, Moorhead JF 1981 Hyperlipidaemia in untreated nephrotic syndrome, increased production or decreased removal? Clin Chim Acta 117: 317-323
6. Chan MK, Presaud JW, Varghese Z, Moorhead JF 1984 Post-heparin hepatic and lipoprotein lipase activities in nephrotic syndrome. Aust NZ J Med 14: 841-847
7. Curry RC, Roberts WC 1977 Status of the coronary arteries in the nephrotic syndrome. Am J Med 63: 183-192
8. Diamond JR, Karnovsky MJ 1987 Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. Kid Int 32: 671-677
9. Elisaf M, Dardamanis M, Pappas M, Sferopoulos G, Siamopoulos KC 1991 Treatment of nephrotic hyperlipidemia with lovastatin (letter). Clin Nephrol 36: 50-52
10. Gerber GW, Gottlieb A, Marsh JB, Sparks CE 1984 Catabolism of very low density lipoproteins in experimental nephrosis. J Clin Invest 74: 1375-1383
11. Gherardi E, Vechia L, Calandra S 1980 Experimental nephrotic syndrome in the rat induced by puromycin aminonucleoside. Plasma and urinary lipoproteins. Exp Mol Path 32: 128-142
12. Golper TA, Illingworth DR, Morris CD, Bennett WM 1989 Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. Am J Kid Dis 13: 312-320
13. 51Cr-EDTA clearance determined by one plasma sample. Clin Physiol 1: 417-425
14. Havel RJ, Hunninghake DB, Illingworth R et al. 1987 Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesteroelemia. A multicentre study. Ann Int Med 107: 609-615
15. Iida H, Asaka M, Fujita M, Nishino A, Sasayama S 1987 Effect of probucol on hyperlipidaemia in patients with nephrotic syndrome. Nephron 47: 280-283
16. Kashyap MI, Srivastava LS, Hynd BA et al. 1980 Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 35: 29-40
17. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF 1988 Treatment of hyperlipidaemia reduces glomerular injury in obese Zucker rats. Kid Int 33: 667-672
18. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF 1988 Pharmacologic treatment of hyperlipidaemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 62: 367-373
19. Lewis B 1983 The lipoproteins: predictors, protectors, and pathogens. Br Med J 287: 1161-1164
20. Mallick NP, Short CD 1981 The nephrotic syndrome and ischaemic heart disease. Nephron 27: 54-57
21. Marsh JB 1984 Lipoprotein metabolism in experimental nephrosis. J Lipid Res 25: 1619-1623
22. Morosaki N, Matsuoka N, Saito Y, Kumagai A 1984 Lipid metabolism in nephrotic rats induced by daunomycin injection. Metabolism 33: 405-410
23. Muls E, Rosseneu M, Daneels K, Schurgers M, Boelaert J 1985 Lipoprotein distribution in the human nephrotic syndrome. Atherosclerosis 54: 225-237
24. Ponticelli C, Zucchelli P, Passerini et al. 1989 A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320: 8-13
25. Rabelink AJ, Hene RJ, Erkelens DW, Joles JA 1988 Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 2: 1335-1338
26. Schaefer EJ, Levy RI 1985 Pathogenesis and management of lipoprotein disorders. N Engl J Med 312: 1300-1310
27. Schieppati A, Mosconi L, Perna A et al. 1993 Prognosis of untreated idiopathic membranous nephropathy. N Engl J Med 329: 85-89
28. Thomas ME, Harris KPG, Ramaswamy C et al. 1993 Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kid Int 44: 1124-1129
29. Valeri A, Gelfand J, Blum C, Appel GB 1986 Treatment of the hyperlipidaemia of the nephrotic syndrome: a controlled trial. Am J Kid Dis 8: 388-396
30. Vega GL, Grundy SM 1988 Lovastatin therapy in nephrotic hyperlipidaemia: effects on lipoprotein metabolism. Kid Int 33: 1160-1168
31. Wanner C, Boher J, Eckardt HG, Wieland H, Schollmeyer P 1994 Clin Nephrol 41: 138-143